In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin

Papers of special note have been highlighted as: • of interest

References

• 1. Rutter WC, Burgess DR, Burgess DS. Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates. Microb. Drug Resist. 23(1), 51–55 (2017).
  Medline CASGoogle Scholar
• 2. Vasiljevic ZV, Novovic K, Kojic M et al. Burkholderia cepacia complex in serbian patients with cystic fibrosis: prevalence and molecular epidemiology. Eur. J. Clin. Microbiol. Infect. Dis. 35(8), 1277–1284 (2016).
  Medline CASGoogle Scholar
• 3. Farfour E, Trochu E, Devin C et al. Trends in ceftazidime–avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients. Transpl. Infect. Dis. 20(5), e12955 (2018). • The manuscript describes ceftazidime–avibactam in vitro activity against Burkholderia, Achromobacter and Stenotrophomonas.
  MedlineGoogle Scholar
• 4. Massip C, Mathieu C, Gaudru C et al. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 74(2), 525–528 (2019).
  Medline CASGoogle Scholar
• 5. Bonacorsi S, Fitoussi F, Lhopital S et al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43(2), 213–217 (1999).
  Medline CASGoogle Scholar
• 6. Lomovskaya O, Sun D, Rubio-Aparicio D et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother. 61(11), 17–32 (2017).
  Google Scholar
• 7. Tsivkovski R, Lomovskayaa O. Biochemical activity of vaborbactam. Antimicrob. Agents Chemother. 64(2), 19–27 (2020).
  Google Scholar
• 8. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect. Dis. Ther. 7(4), 439–455 (2018).
  MedlineGoogle Scholar
• 9. Romanelli F, Stolfa S, Morea A et al. Meropenem–vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment. Future Microbiol. 16(16), 1261–1266 (2021).
  CASGoogle Scholar
• 10. Bassetti M, Pecori D, Cojutti P et al. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opin. Drug Metab. Toxicol. 13(11), 1193–1200 (2017).
  Medline CASGoogle Scholar
• 11. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters version 11.0 (2021). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf
  Google Scholar
• 12. Clinical and laboratory Standard Institute (2020). https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf
  Google Scholar
• 13. Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem–vaborbactam, or both? Clinical and formulary considerations. Clin. Infect. Dis. 68(3), 519–524 (2019).
  Medline CASGoogle Scholar
• 14. Caverly LJ, Spilker T, Kalikin LM et al. In vitro activities of β-lactam-β-lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens. Antimicrob. Agents Chemother. 64(1), 19–22 (2020). • The manuscript describes the in vitro activity of 15 drugs against Burkholderia, Achromobacter and Stenotrophomonas.
  Google Scholar
• 15. Moriceau C, Eveillard M, Lemarié C, Chenouard R, Pailhoriès H, Kempf M. Stenotrophomonas maltophilia susceptibility to ceftazidime–avibactam combination versus ceftazidime alone. Med. Mal. Infect. 50(3), 305–307 (2020).
  Medline CASGoogle Scholar
• 16. Biagi M, Tan X, Wu T et al. Activity of potential alternative treatment agents for Stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or trimethoprim–sulfamethoxazole. J. Clin. Microbiol. 58(2), 9–18 (2020).
  Google Scholar
• 17. Ruppé É, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann. Intensive Care 5(1), 61 (2015).
  MedlineGoogle Scholar
• 18. Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist. Updat. 28, 82–90 (2016).
  MedlineGoogle Scholar
• 19. Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin. Respir. Crit. Care Med. 36(1), 99–110 (2015).
  MedlineGoogle Scholar
• 20. European Committee on Antimicrobial Susceptibility Testing. Stenotrophomonas maltophilia (2012). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/S_maltophilia_EUCAST_guidance_note_20120201.pdf
  Google Scholar
• 21. European Committee on Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing of Burkholderia cepacia complex (BCC) (2013). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/BCC_susceptibility_testing_130719.pdf
  Google Scholar
• 22. Wootton M, Davies L, Pitman K, Howe RA. Evaluation of susceptibility testing methods for Burkholderia cepacia complex: a comparison of broth microdilution, agar dilution, gradient strip and EUCAST disc diffusion. Clin. Microbiol. Infect. 27(5), 788.e1–788.e4 (2021). • The manuscript highlights difficulties of performing antimicrobial susceptibility testing of Burkholderia.
  CASGoogle Scholar
• 23. Sfeir MM. Antimicrobial susceptibility testing for glucose-nonfermenting Gram-negative bacteria: the tip of the iceberg. Antimicrob. Agents Chemother. 64(4), 1–2 (2020).
  Google Scholar